Who we are

ProFem is a Vienna based pharmaceutical company founded in 2012 with the focus on the clinical development of innovative drugs for the treatment of gynecological diseases.

Our main focus, especially with the lead candidate “Candiplus®”, lies on infections of the lower urogenital tract, diseases which are frequently associated with the growth of so-called biofilms. This group of infections represents a huge and so far unsolved medical problem in gynecology.


ProFem starts from the medical need of patients who suffer significantly from their respective diseases. ProFem uses state-of-the-art science to develop novel treatment concepts and drugs to improve the health, wellbeing and quality of life of our patients. We want to become innovation leader in the field of gynecology.


ProFem_Website_Home_200px Marion Noe-Letschnig, Founder, CEO

Chemist and medical doctor, specialized in gynecology and obstetrics (gynecological endocrinology and reproductive medicine), research on uterine physiology and pathophysiology, about 10 years of clinical experience.
More than 10 years of professional experience in start-up companies: project management of chemical development projects (API production, GMP documentation), CEO of start-up companies (pharmaceutical R&D) since 2004, financial administration, fund raising, licensing agreements.
Ghazaleh Gouya, CMO

Board certified in Internal Medicine, Cardiology and Clinical Pharmacology MD, more than 15 years of clinical and clinical research experience  (UK and Austria), almost 2 years of experience at a leading CRO as a leader of Medical Monitoring groups. Associate Professor for Internal Medicine, Medical University Vienna since March 2015.  Leader of clinical development in Profem, setting up and managing the clinical development program, including relations to competent authorities, clinical operations team and study centers.


Best of Biotech 2010
“One of the 3 best business concepts”, finalist in the second round of the competition

Fempower 2012
“Best Project”

Supported by INITS, AWS, Vienna Business Agency


csm_Senat_Swetly_Portrait_01_7d07499947_200px Peter Swetly

Former director of Research and Development of Boehringer Ingelheim Austria, in this function one of the main initiators of the foundation of the Institute of Molecular Pathology (IMP) and the Biocenter of the University of Vienna. Broad international experience in the development of innovative medicines from discovery to registration.
Christian Noe200px Christian Noe

Studies of technical chemistry, pharmacy; former Head of the Departments of Medicinal Chemistry, Universities of Frankfurt and Vienna. Broad experience in organic and medicinal chemistry, drug discovery and development and translational sciences related to this field. Additional expertise: former advisor to UNIDO and IAEA, former president of EUFEPS, first chairman of the scientific committee of IMI.
Andreas Jank_200px Andreas Jank

Andreas Jank is attorney at law with a focus on pharmaceutical law, corporate finance and M&A. He is founding partner of Jank Weiler Operenyi attorneys at law that ranked best boutique law firm for corporate finance and M&A in Austria in 2014.